Janssen, Celltrion Brawl Over Fed. Circ. Biosimilar Ruling

By Jeff Overley (August 26, 2015, 7:43 PM EDT) -- Janssen Biotech Inc. and Celltrion Inc. are squaring off in Massachusetts federal court with competing views of a recent Federal Circuit interpretation of the Biologics Price Competition and Innovation Act, debating whether it made advance-notice of biosimilar marketing mandatory in all circumstances.

The competing views were expressed in documents filed this week as part of patent infringement litigation that Janssen launched earlier this year to delay Celltrion's proposed biosimilar version of blockbuster biologic Remicade. At issue is whether the Federal Circuit's recent ruling in Amgen Inc. v. Sandoz Inc. made the BPCIA's 180-day advance-notice provision mandatory even when a biosimilar maker participates...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!